论文部分内容阅读
目的观察依达拉奉治疗急性脑梗死后出血转化的临床效果。方法急性脑梗死后出血转化患者86例随机均分为两组:对照组采用溶栓、抗凝和扩血管等常规治疗;试验组加用依达拉奉30mg加入100ml生理盐水,静脉滴注30min;每天2次,治疗21d。比较两组患者的临床疗效。结果治疗21d后,试验组患者的脑血肿、脑水肿体积均小于对照组(P<0.01),神经功能缺损评分低于对照组(P<0.01)。试验组总有效率高于对照组(88.4%vs.67.4%)(P<0.05)。治疗过程中两组患者未见明显不良反应发生。结论在常规治疗的基础上加用依达拉奉治疗能进一步降低急性脑梗死后出血转化患者的脑血肿、脑水肿体积,改善神经功能缺损。
Objective To observe the clinical effect of edaravone in the treatment of hemorrhage after acute cerebral infarction. Methods Eighty-six patients with hemorrhage after acute cerebral infarction were randomly divided into two groups: the control group received routine therapy such as thrombolysis, anticoagulation and vasodilatation; in the experimental group, Edaravone 30mg plus 100ml normal saline, intravenous infusion 30min ; 2 times a day, treatment 21d. The clinical efficacy of the two groups was compared. Results After 21 days of treatment, the volume of cerebral hematoma and brain edema in the experimental group was smaller than that of the control group (P <0.01), and the score of neurological deficit was lower than that of the control group (P <0.01). The total effective rate of the experimental group was higher than that of the control group (88.4% vs.67.4%) (P <0.05). No significant adverse reactions occurred in both groups during the course of treatment. Conclusion The addition of edaravone to conventional treatment can further reduce the volume of cerebral hematoma and brain edema in patients with hemorrhage after acute cerebral infarction and improve neurological deficits.